Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Misses on Revenue, Stock Up 2.85%

Vertex Pharmaceuticals reported an EPS of $-0.82, which was slightly better than expected, leading to a stock increase of 2.85%. However, no revenue figures were provided, leaving investors without a complete picture of the company's performance. The lack of guidance and management commentary may lead to uncertainty among investors moving forward.